![Survival curve by Kaplan-Meier presented median survival time at 36... | Download Scientific Diagram Survival curve by Kaplan-Meier presented median survival time at 36... | Download Scientific Diagram](https://www.researchgate.net/publication/334264818/figure/fig3/AS:777484761038853@1562378220111/Survival-curve-by-Kaplan-Meier-presented-median-survival-time-at-36-hours-n-21.png)
Survival curve by Kaplan-Meier presented median survival time at 36... | Download Scientific Diagram
![Predicting Mean Survival Time from Reported Median Survival Time for Cancer Patients | Semantic Scholar Predicting Mean Survival Time from Reported Median Survival Time for Cancer Patients | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/972182572e265b32a4a6daeeb5035fe082957c8a/3-Figure1-1.png)
Predicting Mean Survival Time from Reported Median Survival Time for Cancer Patients | Semantic Scholar
![Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real‐life data - Hamers - 2021 - International Journal of Cancer - Wiley Online Library Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real‐life data - Hamers - 2021 - International Journal of Cancer - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/f7f5ef91-7444-46b6-bc9c-8ddcbe7a3fe5/ijc33200-fig-0001-m.jpg)
Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real‐life data - Hamers - 2021 - International Journal of Cancer - Wiley Online Library
![Restricted Mean Survival Time: An Obligatory End Point for Time-to-Event Analysis in Cancer Trials? | Journal of Clinical Oncology Restricted Mean Survival Time: An Obligatory End Point for Time-to-Event Analysis in Cancer Trials? | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2016/jco.2015.64.34.issue-28/jco.2016.67.8045/20161107/images/medium/jco678045t1.gif)
Restricted Mean Survival Time: An Obligatory End Point for Time-to-Event Analysis in Cancer Trials? | Journal of Clinical Oncology
![Using the Restricted Mean Survival Time Difference as an Alternative to the Hazard Ratio for Analyzing Clinical Cardiovascular Studies | Circulation Using the Restricted Mean Survival Time Difference as an Alternative to the Hazard Ratio for Analyzing Clinical Cardiovascular Studies | Circulation](https://www.ahajournals.org/cms/asset/2130035e-4ca7-4341-a6eb-e64b80004f96/1366fig01.gif)
Using the Restricted Mean Survival Time Difference as an Alternative to the Hazard Ratio for Analyzing Clinical Cardiovascular Studies | Circulation
![Predicting Mean Survival Time from Reported Median Survival Time for Cancer Patients - Mette L. Lousdal, Ivar Sønbø Kristiansen, Bjørn Møller, Henrik Støvring, 2017 Predicting Mean Survival Time from Reported Median Survival Time for Cancer Patients - Mette L. Lousdal, Ivar Sønbø Kristiansen, Bjørn Møller, Henrik Støvring, 2017](https://journals.sagepub.com/cms/10.1177/0272989X16655341/asset/images/large/10.1177_0272989x16655341-fig2.jpeg)
Predicting Mean Survival Time from Reported Median Survival Time for Cancer Patients - Mette L. Lousdal, Ivar Sønbø Kristiansen, Bjørn Møller, Henrik Støvring, 2017
![JCI Insight - Systems pharmacology–based integration of human and mouse data for drug repurposing to treat thoracic aneurysms JCI Insight - Systems pharmacology–based integration of human and mouse data for drug repurposing to treat thoracic aneurysms](https://df6sxcketz7bb.cloudfront.net/manuscripts/127000/127652/medium/jci.insight.127652.f3.jpg)